Product Reviews
Categories
- Alternative Medicine
- Cancer
- Acute Promyelocytic Leukemia
- Anal Cancer
- Bladder Cancer
- Breast cancer
- Colorectal cancer
- Endometrial Cancer
- Esophageal Cancer
- Gallbladder cancer
- Gastric Cancer
- Glioblastma
- Head and Neck Cancer
- Liver Cancer
- Lung Cancer
- Lymphoma
- Melanoma
- Nasopharyngeal Cancer
- Non-Hodgkin's Disease
- Ovarian Cancer
- Pancreatic Cancer
- Prostate cancer
- Renal Cancer
- Thyroid Cancer
- Cardiovascular disease
- Central Nervous System
- Constipation
- Diabetes
- Fatty Liver
- Irritable Bowel Syndrome
- Longevity
- Motherhood
- Obesity
- Others
- Psoriasis
- Respiratory Disease
- Rheumatoid Arthritis
Archives
Tag Archives: Bristol-Myers Squibb
Anorexia and Cachexia – Causes, Symptoms, Diagnosis, Prognosis and Latest Treatment
Anorexia in Cancer Cancer anorexia-cachexia syndrome (CACS) is an extremely common condition in cancer patients. It is estimated that 50% of cancer patients suffered from anorexia. The exact frequency of CACS varies according to the primary pathology (from 30% in … Continue reading →
Posted in Cancer, Gastric Cancer, Others, Pancreatic Cancer
|
Tagged AIDS, Anorexia, Bristol-Myers Squibb, Cachexia, Causes, chemotherapy, cyprohetadine, Diagnosis, dronabinol, Gastric Cancer, Lymphoma, malnutrition, Marinol, Megace, megestrol, Merck, Metastatic breast cancer, orexigenic, Oxandrin, oxandrolone, Pancreatic Cancer, Periactin, Prognosis, Symptoms, Treatment, Unimed, wasting
|
2 Comments
FDA Approves Halaven for Late-Stage Breast Cancer
Good news for patients with late stage metastatic breast cancer. The US Food and Drug Administration (FDA) approved eribulin mesylate injection (Halaven; Eisai, Inc) for the treatment of metastatic breast cancer in patients who have received at least 2 prior … Continue reading →
Posted in Breast cancer, Cancer
|
Tagged anthracycline, Bristol-Myers Squibb, capecitabine, chemotherapy, Eisai, eribulin, Halaven, ixabepilone, Ixempra, Metastatic breast cancer, paclitaxel, resistant, Roche, Survival, taxane, Xeloda
|
Comments Off on FDA Approves Halaven for Late-Stage Breast Cancer
